RT Journal Article SR Electronic T1 Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments JF Disease Models & Mechanisms JO Dis Models Mech FD The Company of Biologists Limited SP 727 OP 732 DO 10.1242/dmm.007724 VO 4 IS 6 A1 Draoui, Nihed A1 Feron, Olivier YR 2011 UL http://dmm.biologists.org/content/4/6/727.abstract AB Hypoxia and oncogene expression both stimulate glycolytic metabolism in tumors, thereby leading to lactate production. However, lactate is more than merely a by-product of glycolysis: it can be used as a metabolic fuel by oxidative cancer cells. This phenomenon resembles processes that have been described for skeletal muscle and brain that involve what are known as cell-cell and intracellular lactate shuttles. Two control points regulate lactate shuttles: the lactate dehydrogenase (LDH)-dependent conversion of lactate into pyruvate (and back), and the transport of lactate into and out of cells through specific monocarboxylate transporters (MCTs). In tumors, MCT4 is largely involved in hypoxia-driven lactate release, whereas the uptake of lactate into both tumor cells and tumor endothelial cells occurs via MCT1. Translating knowledge of lactate shuttles to the cancer field offers new perspectives to therapeutically target the hypoxic tumor microenvironment and to tackle tumor angiogenesis.